S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$16.10
+0.30 (+1.90%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.72
$16.22
50-Day Range
$14.76
$21.05
52-Week Range
$5.58
$22.11
Volume
1.69 million shs
Average Volume
3.36 million shs
Market Capitalization
$1.68 billion
P/E Ratio
26.39
Dividend Yield
N/A
Price Target
$20.38

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
26.6% Upside
$20.38 Price Target
Short Interest
Healthy
10.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.80mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$14.87 M Sold Last Quarter
Proj. Earnings Growth
86.11%
From $0.72 to $1.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.04 out of 5 stars

Medical Sector

18th out of 1,028 stocks

Pharmaceutical Preparations Industry

7th out of 501 stocks

CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (CPRX)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
2 Biotechs Making Waves With A Single Product in their Pipeline (CPRX)
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
3 Reasons Growth Investors Will Love Catalyst (CPRX)
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$20.38
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+26.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$39.48 million
Pretax Margin
44.08%

Debt

Sales & Book Value

Annual Sales
$191.76 million
Cash Flow
$0.39 per share
Book Value
$2.01 per share

Miscellaneous

Free Float
89,397,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.17

Social Links


Key Executives

  • Patrick J. McEnanyPatrick J. McEnany
    Chairman, President & Chief Executive Officer
  • Steven R. MillerSteven R. Miller
    Chief Operating & Scientific Officer
  • Alicia GrandeAlicia Grande
    CFO, Treasurer, Principal Accounting Officer & VP
  • Gary IngenitoGary Ingenito
    Chief Medical & Regulatory Officer
  • Stanley Iyadurai
    Vice President-Clinical Development













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $24.00. On average, they predict the company's share price to reach $20.38 in the next year. This suggests a possible upside of 26.6% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 on January 1st, 2023. Since then, CPRX stock has decreased by 13.4% and is now trading at $16.10.
View the best growth stocks for 2023 here
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. The biopharmaceutical company had revenue of $57.24 million for the quarter, compared to the consensus estimate of $53.80 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.40%), Artemis Investment Management LLP (0.25%), State of New Jersey Common Pension Fund D (0.13%), Fisher Asset Management LLC (0.13%), Navellier & Associates Inc. (0.11%) and Cyndeo Wealth Partners LLC (0.10%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $16.10.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.68 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 2/5/2023 by MarketBeat.com Staff